Form 8-K - Current report

0001818844false00018188442024-06-182024-06-18

​

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

​

Date of Report (Date of earliest event reported):  June 18, 2024

​

VIRIOS THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

​

​	​	​
Delaware	001-39811	85-4314201
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

​

​ ​	​
44 Milton Avenue Alpharetta, GA	30009
(Address of principal executive offices)	(Zip Code)

​

Registrant’s telephone number, including area code:  [phone]

​

(Former name or former address, if changed since last report): Not Applicable

​

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001	VIRI	Nasdaq Capital Market

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

​	​
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
​	​
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
​	​
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
​	​
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company     ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       ☐

​

​

​

​

​

​	​
Item 5.07	Submission of Matters to a Vote of Security Holders.

On June 18, 2024, Virios Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). Present at the Annual Meeting in person or by proxy were holders of 8,699,494 shares of common stock of the Company, representing 45.17% of the voting power of the shares of common stock of the Company as of the close of business on April 23, 2024, the record date for the Annual Meeting, and constituting a quorum for the transaction of business. All matters voted upon at the Annual Meeting were approved with the required votes. The matters that were voted upon at the Annual Meeting, and the number of votes cast for, withheld or against, as well as the number of abstentions and broker non-votes, as to each such matter are set forth below.

1. Election of Directors.

The following six nominees were elected to serve as directors of the Company, with the following votes tabulated:

​

​ ​

For

Withheld

Broker Non-Vote

Richard Burch

3,201,273

205,492

5,292,729

Abel De La Rosa, Ph.D.

2,440,247

966,518

5,292,729

Greg Duncan

3,183,237

223,528

5,292,729

David Keefer

3,198,840

207,925

5,292,729

John C. Thomas, Jr.

​

​

3,201,528

​

​

​

205,237

​

​

​

5,292,729

​

Richard J. Whitley, M.D.

​

​

1,964,627

​

​

​

1,442,138

​

​

​

5,292,729

​

​

2. Ratification of the appointment of FORVIS, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

The appointment of FORVIS, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified, with the following votes tabulated:

​

For				Against				Abstain				Broker Non-Vote
	8,347,686				241,056				110,752				—

​

​

​ ​ ​ ​

​

​

​

2

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	​	​
	VIRIOS THERAPEUTICS, INC.
	By:	/s/ Angela Walsh
	Name:	Angela Walsh
​	Title:	Senior Vice President of Finance, Corporate Secretary and Treasurer
June 20, 2024	​	​

​

​

​

3

Document and Entity Information	Jun. 18, 2024
Document and Entity Information [Abstract]
Document Type	8-K
Document Period End Date	Jun. 18, 2024
Entity File Number	001-39811
Entity Registrant Name	VIRIOS THERAPEUTICS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-4314201
Entity Address, Address Line One	44 Milton Avenue
Entity Address, City or Town	Alpharetta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30009
City Area Code	866
Local Phone Number	620-8655
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.0001
Trading Symbol	VIRI
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Central Index Key	0001818844
Amendment Flag	false

---